Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 14/20 | 0.56 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.48 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23311655 | 0.85 | GPR119 (0.55) | GPR119NPBWR1MCHR1 | |
| SCHEMBL639943 | 0.85 | GPR119 (0.63) | GPR119 | |
| SCHEMBL20137483 | 0.85 | GPR119 (0.52) | GPR119NPBWR1MCHR1 | |
| SCHEMBL21606937 | 0.85 | GPR119 (0.52) | GPR119NPBWR1MCHR1 | |
| SCHEMBL19504087 | 0.84 | GPR119 (0.54) | GPR119NPBWR1MCHR1HPGD | |
| SCHEMBL4713304 | 0.84 | GPR119 (0.62) | GPR119 | |
| SCHEMBL4264039 | 0.84 | GPR119 (0.51) | GPR119NPBWR1MCHR1 | |
| SCHEMBL2775170 | 0.84 | GPR119 (0.54) | GPR119 | |
| SCHEMBL18475482 | 0.84 | GPR119 (0.51) | GPR119NPBWR1MCHR1 | |
| SCHEMBL14004872 | 0.84 | GPR119 (0.51) | GPR119NPBWR1MCHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11213525-B2 | Linear glycosidase inhibitors | ASCENEURON SA (CH) | 2022-01-04 | — | — | US | disclosed |
| US-11213525-B2 | Linear glycosidase inhibitors | ASCENEURON SA (CH) | 2022-01-04 | — | — | US | disclosed |
| US-20210077488-A1 | LINEAR GLYCOSIDASE INHIBITORS | ASCENEURON SA (CH) | 2021-03-18 | — | — | US | disclosed |
| US-20210077488-A1 | LINEAR GLYCOSIDASE INHIBITORS | ASCENEURON SA (CH) | 2021-03-18 | — | — | US | disclosed |
| EP-3672959-A1 | LINEAR GLYCOSIDASE INHIBITORS | Asceneuron SA (CH) | 2020-07-01 | — | — | EP | disclosed |
| WO-2019037860-A1 | LINEAR GLYCOSIDASE INHIBITORS | Asceneuron S.A. (CH) | 2019-02-28 | — | — | WO | disclosed |
| WO-2019037860-A1 | LINEAR GLYCOSIDASE INHIBITORS | Asceneuron S.A. (CH) | 2019-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11213525-B2 | Linear glycosidase inhibitors | ENGASE, GAA, GLA | GPR119 620/4885NPBWR1 945/4885MCHR1 3093/4885 |
| US-20210077488-A1 | LINEAR GLYCOSIDASE INHIBITORS | ENGASE, GAA, GLA | GPR119 620/4885NPBWR1 945/4885MCHR1 3093/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.